A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI)
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Surgery"
DOI: 10.1097/sla.0000000000004102
Abstract: Supplemental Digital Content is available in the text Background and Objective: Reltecimod, a CD 28 T-lymphocyte receptor mimetic, inhibits T-cell stimulation by an array of bacterial pathogens. A previous phase 2 trial demonstrated improved resolution… read more here.
Keywords: resolution; placebo; organ dysfunction; composite endpoint ... See more keywords
Invited Commentary on: Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod.
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Surgery"
DOI: 10.1097/sla.0000000000004135
Abstract: N ecrotizing soft tissue infections represent a tremendously challenging clinical problem with a significant mortality and morbidity. These challenges arise for several reasons. First, delays in diagnosis are common because of the need for both… read more here.
Keywords: controlled trial; trial; randomized controlled; tissue ... See more keywords